FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162974504> ?p ?o ?g. }

• W2162974504 endingPage "490" @default.
• W2162974504 startingPage "483" @default.
• W2162974504 abstract "PURPOSE To determine the effect of omission of cytarabine (ara-C) from treatment of newly diagnosed acute promyelocytic leukemia (APL), which allows administration of more anthracycline. PATIENTS AND METHODS Induction consisted of all-trans retinoic acid (ATRA) 45 mg/m2 daily until complete remission (CR) and idarubicin 12 mg/m2 daily for 4 days beginning on day 5 of ATRA. Patients in CR received two courses of idarubicin 12 mg/m2 daily for 3 days and then, until 2 years post-CR date, alternated three cycles of mercaptopurine, vincristine, methotrexate, and prednisone (POMP) with one cycle of idarubicin 12 mg/m2 daily for 2 days. Results in the 43 patients treated (41 with t(15;17) on standard or Southern analysis) were compared with those in 57 historic newly diagnosed APL patients given ara-C with either doxorubicin, amsacrine (AMSA), or daunorubicin without ATRA, using logistic and Cox regression to assess effects of non-treatment-related covariates on patient outcomes. RESULTS The CR rate in the current group was 77% (95% confidence interval [CI], 62% to 88%) and was not significantly different from the historic rate. In contrast, disease-free survival (DFS) in CR is superior in the current group (probability at 1 year 0.87; 95% CI, 0.73 to 1.0). This has translated into superior overall DFS for the current group (P = .03 adjusting for the predictive covariates initial WBC and platelet count; 1-year DFS probability 0.67; 95% CI, 0.52 to 0.82; median follow-up 102 weeks). The current treatment appears better both in patients with and without t(15; 17) on standard cytogenetic analysis. CONCLUSION Given the difficulties inherent in comparing sequential studies and recognizing the multiple differences in treatment between current and historic groups, our results suggest that a large randomized trial incorporating use of ATRA should assess the utility of omitting ara-C from treatment of newly diagnosed APL, thus allowing delivery of more anthracycline." @default.
• W2162974504 created "2016-06-24" @default.
• W2162974504 creator A5002347804 @default.
• W2162974504 creator A5027575595 @default.
• W2162974504 creator A5057920623 @default.
• W2162974504 creator A5071687115 @default.
• W2162974504 creator A5090435894 @default.
• W2162974504 date "1997-02-01" @default.
• W2162974504 modified "2023-10-18" @default.
• W2162974504 title "Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine." @default.
• W2162974504 cites W1948143034 @default.
• W2162974504 cites W1966714873 @default.
• W2162974504 cites W1977627834 @default.
• W2162974504 cites W1979300931 @default.
• W2162974504 cites W2020214980 @default.
• W2162974504 cites W2024081693 @default.
• W2162974504 cites W2031330193 @default.
• W2162974504 cites W2046657068 @default.
• W2162974504 cites W2047157074 @default.
• W2162974504 cites W2054070557 @default.
• W2162974504 cites W2057968703 @default.
• W2162974504 cites W2063384143 @default.
• W2162974504 cites W2086224692 @default.
• W2162974504 cites W2115902030 @default.
• W2162974504 cites W2139984188 @default.
• W2162974504 cites W2163687510 @default.
• W2162974504 cites W2172665548 @default.
• W2162974504 cites W2180813806 @default.
• W2162974504 cites W2276843828 @default.
• W2162974504 cites W2290016363 @default.
• W2162974504 cites W2406231649 @default.
• W2162974504 cites W2418725932 @default.
• W2162974504 cites W54619631 @default.
• W2162974504 cites W579135650 @default.
• W2162974504 cites W79968274 @default.
• W2162974504 cites W2995133996 @default.
• W2162974504 doi "https://doi.org/10.1200/jco.1997.15.2.483" @default.
• W2162974504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9053469" @default.
• W2162974504 hasPublicationYear "1997" @default.
• W2162974504 type Work @default.
• W2162974504 sameAs 2162974504 @default.
• W2162974504 citedByCount "122" @default.
• W2162974504 countsByYear W21629745042012 @default.
• W2162974504 countsByYear W21629745042013 @default.
• W2162974504 countsByYear W21629745042014 @default.
• W2162974504 countsByYear W21629745042015 @default.
• W2162974504 countsByYear W21629745042017 @default.
• W2162974504 countsByYear W21629745042020 @default.
• W2162974504 countsByYear W21629745042023 @default.
• W2162974504 crossrefType "journal-article" @default.
• W2162974504 hasAuthorship W2162974504A5002347804 @default.
• W2162974504 hasAuthorship W2162974504A5027575595 @default.
• W2162974504 hasAuthorship W2162974504A5057920623 @default.
• W2162974504 hasAuthorship W2162974504A5071687115 @default.
• W2162974504 hasAuthorship W2162974504A5090435894 @default.
• W2162974504 hasConcept C104317684 @default.
• W2162974504 hasConcept C121608353 @default.
• W2162974504 hasConcept C126322002 @default.
• W2162974504 hasConcept C141071460 @default.
• W2162974504 hasConcept C185592680 @default.
• W2162974504 hasConcept C2776601000 @default.
• W2162974504 hasConcept C2776694085 @default.
• W2162974504 hasConcept C2776755627 @default.
• W2162974504 hasConcept C2776802502 @default.
• W2162974504 hasConcept C2778041864 @default.
• W2162974504 hasConcept C2778461978 @default.
• W2162974504 hasConcept C2778720950 @default.
• W2162974504 hasConcept C2779117419 @default.
• W2162974504 hasConcept C2779429289 @default.
• W2162974504 hasConcept C2781021840 @default.
• W2162974504 hasConcept C2781121885 @default.
• W2162974504 hasConcept C44249647 @default.
• W2162974504 hasConcept C530470458 @default.
• W2162974504 hasConcept C55493867 @default.
• W2162974504 hasConcept C71924100 @default.
• W2162974504 hasConcept C90924648 @default.
• W2162974504 hasConceptScore W2162974504C104317684 @default.
• W2162974504 hasConceptScore W2162974504C121608353 @default.
• W2162974504 hasConceptScore W2162974504C126322002 @default.
• W2162974504 hasConceptScore W2162974504C141071460 @default.
• W2162974504 hasConceptScore W2162974504C185592680 @default.
• W2162974504 hasConceptScore W2162974504C2776601000 @default.
• W2162974504 hasConceptScore W2162974504C2776694085 @default.
• W2162974504 hasConceptScore W2162974504C2776755627 @default.
• W2162974504 hasConceptScore W2162974504C2776802502 @default.
• W2162974504 hasConceptScore W2162974504C2778041864 @default.
• W2162974504 hasConceptScore W2162974504C2778461978 @default.
• W2162974504 hasConceptScore W2162974504C2778720950 @default.
• W2162974504 hasConceptScore W2162974504C2779117419 @default.
• W2162974504 hasConceptScore W2162974504C2779429289 @default.
• W2162974504 hasConceptScore W2162974504C2781021840 @default.
• W2162974504 hasConceptScore W2162974504C2781121885 @default.
• W2162974504 hasConceptScore W2162974504C44249647 @default.
• W2162974504 hasConceptScore W2162974504C530470458 @default.
• W2162974504 hasConceptScore W2162974504C55493867 @default.
• W2162974504 hasConceptScore W2162974504C71924100 @default.
• W2162974504 hasConceptScore W2162974504C90924648 @default.
• W2162974504 hasIssue "2" @default.

• next